Evidence map›Paper›PMID 40235082›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

The CentiMarker project: Standardizing quantitative Alzheimer's disease fluid biomarkers for biologic interpretation.

Guoqiao Wang, Yan Li, Chengjie Xiong, Yuchen Cao, Suzanne E Schindler, Eric McDade, Kaj Blennow, Oskar Hansson, Jeffrey L Dage, Clifford R Jack and 8 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. The relationship of soluble tau species with Alzheimer's disease amyloid plaque removal and tau pathology.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Guoqiao WangDepartment of Neurology, Washington University, School of Medicine, St. Louis, Missouri, USA.ORCID 0000-0002-6808-8737
Yan LiDepartment of Neurology, Washington University, School of Medicine, St. Louis, Missouri, USA.
Chengjie XiongDivision of Biostatistics, Washington University, School of Medicine, St. Louis, Missouri, USA.
Yuchen CaoDepartment of Neurology, Washington University, School of Medicine, St. Louis, Missouri, USA.
Suzanne E SchindlerDepartment of Neurology, Washington University, School of Medicine, St. Louis, Missouri, USA.
Eric McDadeDepartment of Neurology, Washington University, School of Medicine, St. Louis, Missouri, USA.
Kaj BlennowInstitute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden.
Oskar HanssonClinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden.
Jeffrey L DageDepartment of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Clifford R JackDepartment of Radiology, Mayo Clinic, Rochester, Minnesota, USA.
Charlotte E TeunissenNeurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam University Medical Centers, Vrije Universiteit, Amsterdam Neuroscience, Amsterdam, Netherlands.
Leslie M ShawDepartment of Pathology & Laboratory Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania, USA.
Henrik ZetterbergInstitute of Neuroscience and Physiology, University of Gothenburg, Mölndal, Sweden.
Laura IbanezDepartment of Neurology, Washington University, School of Medicine, St. Louis, Missouri, USA.
Jigyasha TimsinaDepartment of Psychiatry, Washington University, St. Louis, Missouri, USA.
Cruchaga CarlosDepartment of Neurology, Washington University, School of Medicine, St. Louis, Missouri, USA.
Alzheimer's Disease Neuroimaging Initiative
Randall J BatemanDepartment of Neurology, Washington University, School of Medicine, St. Louis, Missouri, USA.

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
Imaging CoreU19AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2010 to 2025
$53.9M
DIAN-TU Next Generation Prevention Trial - Data Request Management SupplementR01AG053267 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2017 to 2023
$34.9M
Dominantly Inherited Alzheimer's Network Trials Unit - Adaptive Prevention TrialR01AG046179 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2014 to 2019
$26.6M
Dominantly Inherited Alzheimer NetworkUF1AG032438 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2014 to 2017
$21.6M
MAPPING THE HUMAN CONNECTOME DURING TYPICAL AGINGU01AG052564 · NIA · WASHINGTON UNIVERSITY · PI SALAT, DAVID H, TERPSTRA, MELISSA J · 2016 to 2020
$18.9M
DOMINANTLY INHERITED ALZHEIMER NETWORK TRIAL: AN OPPORTUNITY TO PREVENT DEMENTIAU01AG042791 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2013 to 2018
$8.9M
DIAN-TU: Next Generation Prevention TrialR56AG053267 · NIA · WASHINGTON UNIVERSITY · PI BATEMAN, RANDALL J · 2016 to 2016
$3.2M
AbbVie, Alzheimer's Association; Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche LtdAlzheimer's AssociationAlzheimer's Disease Neuroimaging InitiativeAvid RadiopharmaceuticalsDepartment of Defense W81XWH-12-2-0012Eli Lilly and CompanyF. Hoffman-LaRoche Ltd.FNIH and Accelerating Medicines Partnership R01AG046179FNIH and Accelerating Medicines Partnership R01AG053267-S1Foundation for the National Institutes of Health U01AG052564Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health ResearchGerman Center for Neurodegenerative Diseases (DZNE)GHR FoundationJapan Agency for Medical Research and Development (AMED)Korea Dementia Research Center (KDRC)Korea Health Industry Development Institute (KHIDI)Korea Health Technology R&DNational Institute on Aging (NIA)NIA NIH HHS R01 AG046179NIA NIH HHS R01 AG053267NIA NIH HHS R56 AG053267NIA NIH HHS U01 AG024904NIA NIH HHS U01 AG042791NIA NIH HHS U01 AG052564NIA NIH HHS U19 AG032438NIA NIH HHS UF1 AG032438NIBIB NIH HHSNIH HHS U01 AG024904NIH HHS U01AG042791-S1Raul Carrea Institute for Neurological Research (FLENI)Spanish Institute of Health Carlos III (ISCIII)The Dominantly Inherited Alzheimer Networkthe Ministry of Health & Welfare and Ministry of Science and ICT, Republic of Korea HI21C0066
6 · The paper itself

Abstract

introductionBiomarkers play a crucial role in understanding Alzheimer's disease (AD) pathogenesis and treatment effects. However, comparing biomarker measures without standardization and appreciating their magnitude relative to the disease can be challenging.

methodsTo address this issue, we propose the CentiMarker approach, similar to Centiloid, which provides a standardized scale between normal (0) and nearly maximum abnormal AD (100) ranges. We applied this scale to cerebrospinal fluid (CSF) biomarkers in dominantly inherited AD and sporadic AD cohorts.

resultsCentiMarkers facilitated the interpretation of disease abnormality, demonstrating comparable changes and distributions of AD biomarkers across disease stages. CentiMarkers make the treatment effect more comparable than their original scales across various biomarkers. DISCUSSION: The versatility of CentiMarkers makes it a valuable tool for standardized biomarker comparison in AD research, enabling informed cross-study comparisons and contributing to accelerated therapeutic development. Adoption of the CentiMarker scale could enhance biomarker reporting and advance our understanding of AD. HIGHLIGHTS: Comparing fluid biomarkers without appreciating their magnitude relative to the disease can be challenging. We propose a CentiMarker metric to standardize biomarker measures from normal (0) and nearly maximum abnormal AD (100) ranges. CentiMarkers make the treatment effect more comparable across various biomarkers than when using the original scales.

Indexed as

Alzheimer DiseaseBiomarkersAgedAmyloid beta-PeptidesFemaleHumansMalePeptide Fragmentstau ProteinsAmyloid beta-PeptidesBiomarkersPeptide Fragmentstau ProteinsAlzheimer's diseasebiomarker standardizationCentiMarkerfluid biomarker

Identifiers

PMID40235082
PMCPMC12000244

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.